Search Results - "O'MEARA, Eileen"

Ferric Carboxymaltose in Heart Failure with Iron Deficiency by Mentz, Robert J., Garg, Jyotsna, Rockhold, Frank W., Butler, Javed, De Pasquale, Carmine G., Ezekowitz, Justin A., Lewis, Gregory D., O’Meara, Eileen, Ponikowski, Piotr, Troughton, Richard W., Wong, Yee Weng, She, Lilin, Harrington, Josephine, Adamczyk, Robert, Blackman, Nicole, Hernandez, Adrian F.

“…In patients with heart failure with reduced ejection fraction and iron deficiency, ferric carboxymaltose therapy did not appear to differ from placebo in the…”
Get full text

Spironolactone Metabolites in TOPCAT — New Insights into Regional Variation by de Denus, Simon, O’Meara, Eileen, Desai, Akshay S, Claggett, Brian, Lewis, Eldrin F, Leclair, Grégoire, Jutras, Martin, Lavoie, Joël, Solomon, Scott D, Pitt, Bertram, Pfeffer, Marc A, Rouleau, Jean L

“…In a subgroup of TOPCAT participants assigned to spironolactone, the spironolactone metabolite canrenone was measured to assess adherence. Canrenone levels…”
Get full text

Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction by Shah, Amil M., Cikes, Maja, Prasad, Narayana, Li, Guichu, Getchevski, Stoyan, Claggett, Brian, Rizkala, Adel, Lukashevich, Ilya, O’Meara, Eileen, Ryan, John J., Shah, Sanjiv J., Mullens, Wilfred, Zile, Michael R., Lam, Carolyn S.P., McMurray, John J.V., Solomon, Scott D.

“…The PARAGON-HF (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction) trial tested the efficacy of…”
Get full text

Fibrosis Biomarkers Predict Cardiac Reverse Remodeling by O'Meara, Eileen, Zannad, Faiez

Get full text

When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease by O’Meara, Eileen, Verma, Subodh

“…The role of sodium-glucose cotransporter 2 (SGLT2) inhibitors in preventing heart failure (HF) in people with type 2 diabetes (T2DM) is now part of current…”
Get full text

Effects of dapagliflozin in DAPA-HF according to background heart failure therapy by Docherty, Kieran F, Jhund, Pardeep S, Inzucchi, Silvio E, Køber, Lars, Kosiborod, Mikhail N, Martinez, Felipe A, Ponikowski, Piotr, DeMets, David L, Sabatine, Marc S, Bengtsson, Olof, Sjöstrand, Mikaela, Langkilde, Anna Maria, Desai, Akshay S, Diez, Mirta, Howlett, Jonathan G, Katova, Tzvetana, Ljungman, Charlotta E A, O’Meara, Eileen, Petrie, Mark C, Schou, Morten, Verma, Subodh, Vinh, Pham Nguyen, Solomon, Scott D, McMurray, John J V

“…Abstract Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death in patients with HF and…”
Get full text

Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial by Pfeffer, Marc A, Claggett, Brian, Assmann, Susan F, Boineau, Robin, Anand, Inder S, Clausell, Nadine, Desai, Akshay S, Diaz, Rafael, Fleg, Jerome L, Gordeev, Ivan, Heitner, John F, Lewis, Eldrin F, O'Meara, Eileen, Rouleau, Jean-Lucien, Probstfield, Jeffrey L, Shaburishvili, Tamaz, Shah, Sanjiv J, Solomon, Scott D, Sweitzer, Nancy K, McKinlay, Sonja M, Pitt, Bertram

“…Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular…”
Get full text

The Role of Ablation-Based Rhythm Control in the Tangled Web of Atrial Fibrillation and Heart Failure by Parkash, Ratika, O’Meara, Eileen, Tang, Anthony S.L.

Get full text

Angiotensin receptor-neprilysin inhibitor vs. placebo in congenital systemic right ventricular heart failure: the PARACYS-RV trial by Chaix, Marie-A, Dore, Annie, Mondésert, Blandine, Mongeon, François-Pierre, Roy, Véronique, Desrosiers-Gagnon, Charles, Guertin, Marie-Claude, White, Michel, Ibrahim, Réda, O'Meara, Eileen, Rouleau, Jean-Lucien, Khairy, Paul

Get full text

Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF by Docherty, Kieran F., Welsh, Paul, Verma, Subodh, De Boer, Rudolf A., O’Meara, Eileen, Bengtsson, Olof, Køber, Lars, Kosiborod, Mikhail N., Hammarstedt, Ann, Langkilde, Anna Maria, Lindholm, Daniel, Little, Dustin J., Sjöstrand, Mikaela, Martinez, Felipe A., Ponikowski, Piotr, Sabatine, Marc S., Morrow, David A., Schou, Morten, Solomon, Scott D., Sattar, Naveed, Jhund, Pardeep S., McMurray, John J.V.

“…Iron deficiency is common in heart failure and associated with worse outcomes. We examined the prevalence and consequences of iron deficiency in the DAPA-HF…”
Get full text

CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction by McDonald, Michael, Virani, Sean, Chan, Michael, Ducharme, Anique, Ezekowitz, Justin A., Giannetti, Nadia, Heckman, George A., Howlett, Jonathan G., Koshman, Sheri L., Lepage, Serge, Mielniczuk, Lisa, Moe, Gordon W., O’Meara, Eileen, Swiggum, Elizabeth, Toma, Mustafa, Zieroth, Shelley, Anderson, Kim, Bray, Sharon A., Clarke, Brian, Cohen-Solal, Alain, D’Astous, Michel, Davis, Margot, De, Sabe, Grant, Andrew D.M., Grzeslo, Adam, Heshka, Jodi, Keen, Sabina, Kouz, Simon, Lee, Douglas, Masoudi, Frederick A., McKelvie, Robert, Parent, Marie-Claude, Poon, Stephanie, Rajda, Miroslaw, Sharma, Abhinav, Siatecki, Kyla, Storm, Kate, Sussex, Bruce, Van Spall, Harriette, Yip, Amelia Ming Ching

“…In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we provide comprehensive recommendations and practical tips for the…”
Get full text

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF by Jackson, Alice M., Dewan, Pooja, Anand, Inder S., Bělohlávek, Jan, Bengtsson, Olof, de Boer, Rudolf A., Böhm, Michael, Boulton, David W., Chopra, Vijay K., DeMets, David L., Docherty, Kieran F., Dukát, Andrej, Greasley, Peter J., Howlett, Jonathan G., Inzucchi, Silvio E., Katova, Tzvetana, Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Lindholm, Daniel, Ljungman, Charlotta E.A., Martinez, Felipe A., O’Meara, Eileen, Sabatine, Marc S., Sjöstrand, Mikaela, Solomon, Scott D., Tereshchenko, Sergey, Verma, Subodh, Jhund, Pardeep S., McMurray, John J.V.

“…BACKGROUND:In the DAPA-HF trial (Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure), the sodium-glucose cotransporter 2 inhibitor dapagliflozin…”
Get full text

Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction by Anand, Inder S., MD, DPhil (Oxon), Claggett, Brian, PhD, Liu, Jiankang, PhD, Shah, Amil M., MD, MPH, Rector, Thomas S., PhD, Shah, Sanjiv J., MD, Desai, Akshay S., MD, MPH, O’Meara, Eileen, MD, Fleg, Jerome L., MD, Pfeffer, Marc A., MD, PhD, Pitt, Bertram, MD, Solomon, Scott D., MD

“…Abstract Objectives The aims of this study were to explore the relationship of baseline levels of natriuretic peptides (NPs) with outcomes and to test for an…”
Get full text

Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF by Cunningham, Jonathan W., Claggett, Brian L., O’Meara, Eileen, Prescott, Margaret F., Pfeffer, Marc A., Shah, Sanjiv J., Redfield, Margaret M., Zannad, Faiez, Chiang, Lu-May, Rizkala, Adel R., Shi, Victor C., Lefkowitz, Martin P., Rouleau, Jean, McMurray, John J.V., Solomon, Scott D., Zile, Michael R.

“…Myocardial fibrosis may contribute to the pathophysiology of heart failure with preserved ejection fraction. Given the biochemical targets of…”
Get full text

Where Are We With Treatment and Prevention of Heart Failure in Patients Post–Myocardial Infarction? by Carberry, Jaclyn, Marquis-Gravel, Guillaume, O’Meara, Eileen, Docherty, Kieran F.

“…As a result of the widespread use of reperfusion therapies and secondary prevention over the last 30 years, there has been a dramatic reduction in the risk of…”
Get full text

Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction by Cunningham, Jonathan W., Vaduganathan, Muthiah, Claggett, Brian L., Kulac, Ian J., Desai, Akshay S., Jhund, Pardeep S., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., McGrath, Martina M., O’Meara, Eileen, Wilderäng, Ulrica, Lindholm, Daniel, Petersson, Magnus, Langkilde, Anna Maria, McMurray, John J.V., Solomon, Scott D.

“…Patients recently hospitalized for heart failure (HF) are at high risk for rehospitalization and death. The purpose of this study was to investigate clinical…”
Get full text

The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis by Ali, Muhammad Usman, Mancini, G B John, Fitzpatrick-Lewis, Donna, Connelly, Kim A, O'Meara, Eileen, Zieroth, Shelley, Sherifali, Diana

“…The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and…”
Get full text

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy by Tardif, Jean-Claude, O'Meara, Eileen, Komajda, Michel, Böhm, Michael, Borer, Jeffrey S., Ford, Ian, Tavazzi, Luigi, Swedberg, Karl

“…Aims The SHIFT echocardiographic substudy evaluated the effects of ivabradine on left ventricular (LV) remodelling in heart failure (HF). Methods and results…”
Get full text

Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial by Shah, Amil M, Shah, Sanjiv J, Anand, Inder S, Sweitzer, Nancy K, O'Meara, Eileen, Heitner, John F, Sopko, George, Li, Guichu, Assmann, Susan F, McKinlay, Sonja M, Pitt, Bertram, Pfeffer, Marc A, Solomon, Scott D

“…Heart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality. Existing data on cardiac structure and function…”
Get full text

Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction: The ROSE Acute Heart Failure Randomized Trial by Chen, Horng H, Anstrom, Kevin J, Givertz, Michael M, Stevenson, Lynne W, Semigran, Marc J, Goldsmith, Steven R, Bart, Bradley A, Bull, David A, Stehlik, Josef, LeWinter, Martin M, Konstam, Marvin A, Huggins, Gordon S, Rouleau, Jean L, O'Meara, Eileen, Tang, W. H. Wilson, Starling, Randall C, Butler, Javed, Deswal, Anita, Felker, G. Michael, O'Connor, Christopher M, Bonita, Raphael E, Margulies, Kenneth B, Cappola, Thomas P, Ofili, Elizabeth O, Mann, Douglas L, Dávila-Román, Víctor G, McNulty, Steven E, Borlaug, Barry A, Velazquez, Eric J, Lee, Kerry L, Shah, Monica R, Hernandez, Adrian F, Braunwald, Eugene, Redfield, Margaret M

“…IMPORTANCE Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute…”
Get full text